Sensus Healthcare (SRTS) Q4 2025 earnings review
Revenue Collapses as Market Freezes for 2026 Reset
Sensus delivered a disastrous Q4 on the surface: Revenue plummeted 62% YoY to $4.9M and the company swung to a $3.2M net loss. However, context is critical. The market effectively froze ahead of a massive regulatory tailwind: a 300% increase in CMS reimbursement rates for SRT delivery that became effective January 1, 2026. Customers—including the company's historically largest account, which purchased zero units—paused orders to await the new economics. The thesis now rests entirely on management's claim that 2026 will see a surge in pent-up demand and a return to full-year profitability.
🐂 Bull Case
Effective Jan 1, 2026, the CMS Physician Fee Schedule increased reimbursement for the SRT delivery code by 300% per fraction. This drastically improves unit economics for dermatologists and removes the 'wait and see' overhang that paralyzed 2025 sales.
While capital sales stalled, the 'Fair Deal Agreement' (FDA) model is working. Treatments delivered surged over 8-fold YoY (11,411 vs 1,367). This shift to recurring revenue reduces lumpiness and proves utilization is rising.
🐻 Bear Case
The company's reliance on a single 'historically largest customer' was exposed brutally. This customer bought zero units in Q4 (vs driving the record Q4'24). Until they return, a massive revenue hole remains.
Gross margins collapsed to 38.8% (from 54.2% a year ago) due to negative operating leverage. If volume doesn't return immediately in Q1'26, Sensus will continue burning cash ($2.4M burned in Q4).
⚖️ Verdict: ⚪
Neutral/Watch. The financial results are ugly, but the specific cause (regulatory pause) is plausible and now resolved. The 300% reimbursement hike is a legitimate catalyst for 2026. Investors should watch Q1 orders closely; if the 'whale' customer doesn't return immediately, the thesis breaks.
Key Themes
Reimbursement Rate Shock (Positive)
The defining narrative for the future is the 2026 CMS Physician Fee Schedule. A 300% per-fraction increase for the delivery code is a structural change to the market. Management notes this provides 'reimbursement certainty' and has already served as a catalyst for new system purchases. This effectively resets the ROI calculation for potential buyers.
Gross Margin Deterioration
The drop in unit volume crushed margins. Gross profit margin fell to 38.8% in Q4 from 54.2% a year ago. Management cited 'lower sales, higher costs of servicing systems, and costs associated with the new placement program.' The service cost increase is particularly concerning as it suggests the installed base is becoming more expensive to maintain even as sales stall.
Single Customer Concentration Risk
The vulnerability of Sensus's sales model was laid bare. The historically largest customer accounted for a massive portion of 2024 volume but purchased nothing in Q4 2025. While Sensus shipped 14 units to others (up from 6 excluding that customer in Q3), the inability to smooth out revenue when the 'whale' pauses is a major structural weakness.
Fair Deal Agreement (FDA) Traction
The pivot to a recurring revenue model is gaining speed. 18 active sites and 10 pending activation show a growing footprint. Most importantly, patient throughput is real: 11,411 treatments in 2025 vs just 1,367 in 2024. This validates that once systems are placed, they are being used, which generates high-margin recurring revenue.
International Diversification
Shipments to China continued in Q4, contributing to the 14 total units. International markets remain a strategic hedge against US reimbursement volatility, though the US market's new rates likely make domestic sales the primary focus for 2026.
R&D Spend Spike
R&D expenses increased to $1.9M (+18% YoY) primarily due to product development for next-gen systems. While innovation is necessary, rising expenses during a revenue trough exacerbates the cash burn.
Other KPIs
Stable YoY, but down from $24.5M in Q3 2025, implying a quarterly cash burn of ~$2.4M. With no debt, the runway is sufficient for now, but a return to profitability in 2026 is essential to preserve the balance sheet.
A sharp reversal from +$1.9M in Q4 2024. This highlights the high fixed-cost nature of the business; when revenue drops 62%, profitability evaporates immediately.
Down from 39 in Q4 2024 (which included 25+ to the large customer). However, shipments excluding the large customer actually improved sequentially from Q3, indicating some underlying demand recovery outside the 'whale' account.
Guidance
Reversing. After a loss-making 2025 ($7.7M net loss), management explicitly targets full-year profitability for 2026. This relies heavily on the reimbursement catalyst converting the pipeline into orders.
Accelerating. Management expects Q1 shipments to exceed Q4 2025 levels. Notably, this guidance assumes *no* contribution from the historically largest customer, suggesting organic growth is restarting.
Key Questions
Large Customer Intentions
The historically largest customer bought zero units in Q4. Have they signaled an intent to resume purchasing in Q1/Q2 now that the 2026 CMS rates are final, or is this relationship permanently scaled back?
FDA Conversion Rate
With the 300% reimbursement hike, does the unit economics shift favor outright capital purchases over the Fair Deal Agreement (FDA) model? How does this impact the recurring revenue strategy?
Gross Margin Recovery
Gross margins dipped below 40%. At what revenue run-rate does the company expect margins to return to the historical 55-60% range?